Zenapax daclizumab: Phase II; marketed to prevent acute organ rejection following renal transplant

Zenapax showed efficacy in a trial of 43 allogeneic bone marrow transplant recipients. The

Read the full 143 word article

How to gain access

Continue reading with a
two-week free trial.